AI assistant
ROCKET PHARMACEUTICALS, INC. — Director's Dealing 2026
Feb 13, 2026
33148_dirs_2026-02-13_3a73dd8b-2747-4386-9bc1-7026d14600d3.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: ROCKET PHARMACEUTICALS, INC. (RCKT)
CIK: 0001281895
Period of Report: 2026-02-11
Reporting Person: Wilson Martin (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2026-02-11 | Common Stock | A | 311813 | — | Acquired | 695629 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2026-02-11 | Stock Option (Right to Buy) | $3.24 | A | 468187 | Acquired | 2036-02-11 | Common Stock (468187) | Direct |
Footnotes
F1: Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis.
F2: Represents RSUs, one-third (1/3) of which will become fully vested on February 11, 2027, with the remaining shares vesting in equal quarterly installments over the following two years.
F3: This option represents a right to purchase a total of 468,187 shares of the Issuer's common stock, one-third of which will become fully vested and exercisable on February 11, 2027, with the remaining shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer.